The United Kingdom's FTSE 100 index has recently faced challenges, closing lower amid concerns over weak trade data from China and its impact on global markets. Despite these broader market fluctuations, investors often seek opportunities in penny stocks, a term that may seem outdated but still holds relevance for those looking to explore growth potential in smaller or newer companies. With a focus on strong financial health and solid fundamentals, penny stocks can offer unique opportunities for growth at lower price points.
Top 10 Penny Stocks In The United Kingdom
| Name | Share Price | Market Cap | Rewards & Risks |
| Foresight Group Holdings (LSE:FSG) | £4.595 | £514.44M | ✅ 4 ⚠️ 0 View Analysis > |
| Warpaint London (AIM:W7L) | £3.15 | £254.48M | ✅ 5 ⚠️ 2 View Analysis > |
| FDM Group (Holdings) (LSE:FDM) | £1.256 | £137.3M | ✅ 2 ⚠️ 4 View Analysis > |
| Van Elle Holdings (AIM:VANL) | £0.41 | £44.36M | ✅ 4 ⚠️ 3 View Analysis > |
| RWS Holdings (AIM:RWS) | £0.894 | £330.58M | ✅ 5 ⚠️ 2 View Analysis > |
| LSL Property Services (LSE:LSL) | £2.70 | £277.48M | ✅ 4 ⚠️ 1 View Analysis > |
| Begbies Traynor Group (AIM:BEG) | £1.17 | £186.24M | ✅ 4 ⚠️ 3 View Analysis > |
| Croma Security Solutions Group (AIM:CSSG) | £0.76 | £10.46M | ✅ 2 ⚠️ 3 View Analysis > |
| Braemar (LSE:BMS) | £2.33 | £71.6M | ✅ 3 ⚠️ 4 View Analysis > |
| Samuel Heath & Sons (AIM:HSM) | £3.35 | £8.49M | ✅ 2 ⚠️ 3 View Analysis > |
Click here to see the full list of 299 stocks from our UK Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
ANGLE (AIM:AGL)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: ANGLE plc is a medical diagnostic company that develops cancer diagnostics products across the United Kingdom, Europe, North America, and internationally, with a market cap of £23.15 million.
Operations: The company generates revenue from its Parsortix segment, amounting to £2.86 million.
Market Cap: £23.15M
ANGLE plc, a medical diagnostic company with a market cap of £23.15 million, is navigating the challenges typical of penny stocks. Despite generating £2.86 million in revenue from its Parsortix segment, ANGLE remains unprofitable and faces doubts about its ability to continue as a going concern due to limited cash runway. Recent collaborations, such as with Myriad Genetics Inc., highlight potential growth avenues but do not immediately resolve financial concerns. The company's debt-free status and seasoned management offer some stability amidst high share price volatility and ongoing executive changes.
- Take a closer look at ANGLE's potential here in our financial health report.
- Review our growth performance report to gain insights into ANGLE's future.
Diaceutics (AIM:DXRX)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Diaceutics PLC is a diagnostic commercialization company that offers data, data analytics, and implementation services to pharma and biotech companies, with a market cap of £118.37 million.
Operations: The company's revenue is derived from its Medical Labs & Research segment, amounting to £32.16 million.
Market Cap: £118.37M
Diaceutics PLC, with a market cap of £118.37 million, remains unprofitable but shows potential in the precision medicine space. The company recently expanded its PMx commercialization partnership, indicating incremental service revenue growth for 2025. Despite an inexperienced board and management team, Diaceutics has no debt and sufficient cash runway for over three years. Analysts are optimistic about a 41% price increase, although the company's negative return on equity highlights profitability challenges. Recent executive appointments aim to bolster leadership as Diaceutics continues to enhance its strategic partnerships within the pharmaceutical sector.
- Jump into the full analysis health report here for a deeper understanding of Diaceutics.
- Learn about Diaceutics' future growth trajectory here.
Mercia Asset Management (AIM:MERC)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Mercia Asset Management PLC is a private equity and venture capital firm that focuses on a wide range of investment stages including incubation, venture debt, and growth capital, with a market cap of £138.07 million.
Operations: The company generates revenue primarily through its Proactive Specialist Asset Management segment, which contributed £35.20 million.
Market Cap: £138.07M
Mercia Asset Management PLC, with a market cap of £138.07 million, has transitioned to profitability, reporting net income of £3.46 million for the year ended March 31, 2025. The company is debt-free and maintains strong liquidity with short-term assets exceeding both short and long-term liabilities. Recent strategic moves include a share buyback program up to £3 million and plans for acquisitions without external funding, reflecting confidence in its financial position. The board's progressive dividend policy continues with an increase to 0.95 pence per share if approved by shareholders in September 2025, indicating sustained cash flow growth.
- Click to explore a detailed breakdown of our findings in Mercia Asset Management's financial health report.
- Examine Mercia Asset Management's earnings growth report to understand how analysts expect it to perform.
Make It Happen
- Click here to access our complete index of 299 UK Penny Stocks.
- Ready To Venture Into Other Investment Styles? Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Diaceutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com